1
|
Zhu H, Lv Y, Xin F, Wang M, Zhao X, Ren X, Zhang J, Yin D, Guo T, Wu L. Enhanced Stability and Solidification of Volatile Eugenol by Cyclodextrin-Metal Organic Framework for Nasal Powder Delivery. AAPS PharmSciTech 2024; 25:117. [PMID: 38806874 DOI: 10.1208/s12249-024-02839-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2024] [Accepted: 05/13/2024] [Indexed: 05/30/2024] Open
Abstract
Eugenol (Eug) holds potential as a treatment for bacterial rhinosinusitis by nasal powder drug delivery. To stabilization and solidification of volatile Eug, herein, nasal inhalable γ-cyclodextrin metal-organic framework (γ-CD-MOF) was investigated as a carrier by gas-solid adsorption method. The results showed that the particle size of Eug loaded by γ-CD-MOF (Eug@γ-CD-MOF) distributed in the range of 10-150 μm well. In comparison to γ-CD and β-CD-MOF, γ-CD-MOF has higher thermal stability to Eug. And the intermolecular interactions between Eug and the carriers were verified by characterizations and molecular docking. Based on the bionic human nasal cavity model, Eug@γ-CD-MOF had a high deposition distribution (90.07 ± 1.58%). Compared with free Eug, the retention time Eug@γ-CD-MOF in the nasal cavity was prolonged from 5 min to 60 min. In addition, the cell viability showed that Eug@γ-CD-MOF (Eug content range 3.125-200 µg/mL) was non-cytotoxic. And the encapsulation of γ-CD-MOF could not reduce the bacteriostatic effect of Eug. Therefore, the biocompatible γ-CD-MOF could be a potential and valuable carrier for nasal drug delivery to realize solidification and nasal therapeutic effects of volatile oils.
Collapse
Affiliation(s)
- Huajie Zhu
- Anhui University of Chinese Medicine, Anhui, 230000, China
- Yangtze Delta Drug Advanced Research Institute, Jiangsu, 226133, China
| | - Yuting Lv
- Anhui University of Chinese Medicine, Anhui, 230000, China
- Yangtze Delta Drug Advanced Research Institute, Jiangsu, 226133, China
| | - Fangyuan Xin
- Yangtze Delta Drug Advanced Research Institute, Jiangsu, 226133, China
- Shenyang Pharmaceutical University, Shenyang, 110016, China
| | - Manli Wang
- Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, Nanchang, 330004, China
| | - Xiangyu Zhao
- Anhui University of Chinese Medicine, Anhui, 230000, China
- Yangtze Delta Drug Advanced Research Institute, Jiangsu, 226133, China
| | - Xiaohong Ren
- Center for Drug Delivery Systems, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China
| | - Jiwen Zhang
- Anhui University of Chinese Medicine, Anhui, 230000, China
- Yangtze Delta Drug Advanced Research Institute, Jiangsu, 226133, China
- Shenyang Pharmaceutical University, Shenyang, 110016, China
- Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, Nanchang, 330004, China
- Center for Drug Delivery Systems, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China
- NMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients, National Institutes for Food and Drug Control, Beijing, 100050, China
| | - Dengke Yin
- Anhui University of Chinese Medicine, Anhui, 230000, China.
| | - Tao Guo
- Center for Drug Delivery Systems, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China.
| | - Li Wu
- Anhui University of Chinese Medicine, Anhui, 230000, China.
- Yangtze Delta Drug Advanced Research Institute, Jiangsu, 226133, China.
- Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, Nanchang, 330004, China.
- Center for Drug Delivery Systems, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China.
- NMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients, National Institutes for Food and Drug Control, Beijing, 100050, China.
| |
Collapse
|
2
|
Wong SN, Li S, Low KH, Chan HW, Zhang X, Chow S, Hui B, Chow PCY, Chow SF. Development of favipiravir dry powders for intranasal delivery: An integrated cocrystal and particle engineering approach via spray freeze drying. Int J Pharm 2024; 653:123896. [PMID: 38346602 DOI: 10.1016/j.ijpharm.2024.123896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2023] [Revised: 01/29/2024] [Accepted: 02/07/2024] [Indexed: 02/17/2024]
Abstract
The therapeutic potential of pharmaceutical cocrystals in intranasal applications remains largely unexplored despite progressive advancements in cocrystal research. We present the application of spray freeze drying (SFD) in successful fabrication of a favipiravir-pyridinecarboxamide cocrystal nasal powder formulation for potential treatment of broad-spectrum antiviral infections. Preliminary screening via mechanochemistry revealed that favipiravir (FAV) can cocrystallize with isonicotinamide (INA), but not nicotinamide (NCT) and picolinamide (PIC) notwithstanding their structural similarity. The cocrystal formation was characterized by differential scanning calorimetry, Fourier-transform infrared spectroscopy, and unit cell determination through Rietveld refinement of powder X-ray analysis. FAV-INA crystalized in a monoclinic space group P21/c with a unit cell volume of 1223.54(3) Å3, accommodating one FAV molecule and one INA molecule in the asymmetric unit. The cocrystal was further reproduced as intranasal dry powders by SFD, of which the morphology, particle size, in vitro drug release, and nasal deposition were assessed. The non-porous flake shaped FAV-INA powders exhibited a mean particle size of 19.79 ± 2.61 μm, rendering its suitability for intranasal delivery. Compared with raw FAV, FAV-INA displayed a 3-fold higher cumulative fraction of drug permeated in Franz diffusion cells at 45 min (p = 0.001). Dose fraction of FAV-INA deposited in the nasal fraction of a customized 3D-printed nasal cast reached over 80 %, whereas the fine particle fraction remained below 6 % at a flow rate of 15 L/min, suggesting high nasal deposition whilst minimal lung deposition. FAV-INA was safe in RPMI 2650 nasal and SH-SY5Y neuroblastoma cells without any in vitro cytotoxicity observed. This study demonstrated that combining the merits of cocrystallization and particle engineering via SFD can propel the development of advanced dry powder formulations for intranasal drug delivery.
Collapse
Affiliation(s)
- Si Nga Wong
- Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region; Advanced Biomedical Instrumentation Centre, Hong Kong Science Park, Shatin, Hong Kong Special Administrative Region
| | - Si Li
- Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region; Advanced Biomedical Instrumentation Centre, Hong Kong Science Park, Shatin, Hong Kong Special Administrative Region
| | - Kam-Hung Low
- Department of Chemistry, Faculty of Science, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region
| | - Ho Wan Chan
- Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region
| | - Xinyue Zhang
- Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region
| | - Stephanie Chow
- Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region
| | - Bo Hui
- Department of Mechanical Engineering, Faculty of Engineering, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region
| | - Philip C Y Chow
- Department of Mechanical Engineering, Faculty of Engineering, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region
| | - Shing Fung Chow
- Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region; Advanced Biomedical Instrumentation Centre, Hong Kong Science Park, Shatin, Hong Kong Special Administrative Region.
| |
Collapse
|
3
|
Kluczka J. Chitosan: Structural and Chemical Modification, Properties, and Application. Int J Mol Sci 2023; 25:554. [PMID: 38203726 PMCID: PMC10779193 DOI: 10.3390/ijms25010554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Accepted: 12/28/2023] [Indexed: 01/12/2024] Open
Abstract
Chitosan is a polymer of natural origins that possesses many favourable properties [...].
Collapse
Affiliation(s)
- Joanna Kluczka
- Department of Inorganic Chemistry, Analytical Chemistry and Electrochemistry, Silesian University of Technology, B. Krzywoustego 6, 44-100 Gliwice, Poland
| |
Collapse
|
4
|
Gagliardi M, Chiarugi S, De Cesari C, Di Gregorio G, Diodati A, Baroncelli L, Cecchini M, Tonazzini I. Crosslinked Chitosan Nanoparticles with Muco-Adhesive Potential for Intranasal Delivery Applications. Int J Mol Sci 2023; 24:ijms24076590. [PMID: 37047562 PMCID: PMC10094788 DOI: 10.3390/ijms24076590] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Revised: 03/22/2023] [Accepted: 03/29/2023] [Indexed: 04/05/2023] Open
Abstract
Intranasal drug delivery is convenient and provides a high bioavailability but requires the use of mucoadhesive nanocarriers. Chitosan is a well-established polymer for mucoadhesive applications but can suffer from poor cytocompatibility and stability upon administration. In this work, we present a method to obtain stable and cytocompatible crosslinked chitosan nanoparticles. We used 2,6-pyridinedicarboxylic acid as a biocompatible crosslinker and compared the obtained particles with those prepared by ionotropic gelation using sodium tripolyphosphate. Nanoparticles were tested to evaluate the size and the surface charge, as well as their stability in storage conditions (4 °C), at the nasal cavity temperature (32 °C), and at the body temperature (37 °C). The crosslinked chitosan nanoparticles showed a size around 150 nm and a surface charge of 10.3 mV ± 0.9 mV, both compatible with the intranasal drug administration. Size and surface charge parameters did not significantly vary over time, indicating the good stability of these nanoparticles. We finally tested their cytocompatibility in vitro using SHSY5Y human neuroblastoma and RPMI 2650 human nasal epithelial cells, with positive results. In conclusion, the proposed synthetic system shows an interesting potential as a drug carrier for intranasal delivery.
Collapse
Affiliation(s)
- Mariacristina Gagliardi
- National Enterprise for nanoScience and nanoTechnology (NEST), Nanoscience Institute—National Research Council (CNR) and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy
| | - Sara Chiarugi
- National Enterprise for nanoScience and nanoTechnology (NEST), Nanoscience Institute—National Research Council (CNR) and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy
| | - Chiara De Cesari
- National Enterprise for nanoScience and nanoTechnology (NEST), Nanoscience Institute—National Research Council (CNR) and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy
| | - Giulia Di Gregorio
- National Enterprise for nanoScience and nanoTechnology (NEST), Nanoscience Institute—National Research Council (CNR) and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy
| | - Alessandra Diodati
- National Enterprise for nanoScience and nanoTechnology (NEST), Nanoscience Institute—National Research Council (CNR) and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy
| | - Laura Baroncelli
- Institute of Neuroscience, National Research Council (CNR), Via Giuseppe Moruzzi 1, 56124 Pisa, Italy
- Department of Developmental Neuroscience, Scientific Institute Stella Maris Foundation, Viale del Tirreno 331, Calambrone, 56128 Pisa, Italy
| | - Marco Cecchini
- National Enterprise for nanoScience and nanoTechnology (NEST), Nanoscience Institute—National Research Council (CNR) and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy
| | - Ilaria Tonazzini
- National Enterprise for nanoScience and nanoTechnology (NEST), Nanoscience Institute—National Research Council (CNR) and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy
| |
Collapse
|